HealthCo Healthcare & Wellness REIT (ASX:HCW) Announces 1H FY25 Results
HealthCo Healthcare & Wellness REIT (ASX:HCW) reports a 5% growth in FFO/unit and DPU for 1H FY25, reaffirming its FY25 guidance.
HealthCo Healthcare & Wellness REIT (ASX:HCW) reports a 5% growth in FFO/unit and DPU for 1H FY25, reaffirming its FY25 guidance.
AVITA Medical (ASX:AVH) reports a 30% revenue increase in Q4 and FDA approvals, setting the stage for significant growth in FY 2025.
Cochlear Limited (ASX:COH) reports a 5% revenue increase and an 8% interim dividend rise for the half year ended December 2024.
RECCE PHARMACEUTICALS Ltd (ASX:RCE) has temporarily paused trading in its securities pending a further announcement.
Althea Group Holdings (ASX:AGH) revises its FY25 revenue guidance to $26-$33 million and adjusts EBITDA expectations amidst strategic restructuring.
Neurotech International Ltd (ASX:NTI) signs a development agreement with RH Pharma to develop cannabinoid therapies for pediatric neurological disorders.
Micro-X Limited (ASX:MX1) raises $6.0M through entitlement and placement offers to advance its medical imaging technology.
Pro Medicus Limited (ASX:PME) reports a 42.7% increase in after-tax profit and announces a fully franked interim dividend.
Nuchev Limited (ASX:NUC) appoints Nathan Cheong as CEO, while Mick Myers transitions to COO and CFO roles.
Artrya Limited (ASX:AYA) secures a three-year agreement with Sonic Healthcare Australia to implement its Salix® platform for coronary artery disease assessment.